Charles River Laboratories International Inc (NYSE: CRL) has a price-to-earnings ratio of 518.89x that is above its average ratio. Additionally, the 36-month beta value for CRL is 1.45. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 16 rating it as “hold,” and 1 rating it as “sell.”
The public float for CRL is 48.54M and currently, short sellers hold a 6.25% ratio of that float. The average trading volume of CRL on May 07, 2025 was 1.73M shares.
CRL) stock’s latest price update
The stock price of Charles River Laboratories International Inc (NYSE: CRL) has surged by 15.32 when compared to previous closing price of 115.41, but the company has seen a 12.20% gain in its stock price over the last five trading sessions. zacks.com reported 2025-05-07 that The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
CRL’s Market Performance
CRL’s stock has risen by 12.20% in the past week, with a monthly drop of -0.73% and a quarterly drop of -19.76%. The volatility ratio for the week is 4.04% while the volatility levels for the last 30 days are 7.95% for Charles River Laboratories International Inc The simple moving average for the past 20 days is 17.53% for CRL’s stock, with a -25.73% simple moving average for the past 200 days.
Analysts’ Opinion of CRL
Many brokerage firms have already submitted their reports for CRL stocks, with Goldman repeating the rating for CRL by listing it as a “Neutral.” The predicted price for CRL in the upcoming period, according to Goldman is $170 based on the research report published on March 21, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see CRL reach a price target of $175, previously predicting the price at $155. The rating they have provided for CRL stocks is “Neutral” according to the report published on March 04th, 2025.
Redburn Atlantic gave a rating of “Neutral” to CRL, setting the target price at $188 in the report published on March 03rd of the current year.
CRL Trading at -6.19% from the 50-Day Moving Average
After a stumble in the market that brought CRL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.63% of loss for the given period.
Volatility was left at 7.95%, however, over the last 30 days, the volatility rate increased by 4.04%, as shares surge +7.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.39% lower at present.
During the last 5 trading sessions, CRL rose by +12.14%, which changed the moving average for the period of 200-days by -39.05% in comparison to the 20-day moving average, which settled at $113.24. In addition, Charles River Laboratories International Inc saw -27.90% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRL starting from FOSTER JAMES C, who purchase 6,075 shares at the price of $165.01 back on Feb 20 ’25. After this action, FOSTER JAMES C now owns 183,639 shares of Charles River Laboratories International Inc, valued at $1,002,436 using the latest closing price.
Girshick Birgit, the Corporate Executive VP & COO of Charles River Laboratories International Inc, purchase 1,514 shares at $164.63 during a trade that took place back on Feb 20 ’25, which means that Girshick Birgit is holding 55,058 shares at $249,250 based on the most recent closing price.
Stock Fundamentals for CRL
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.32 for the gross margin
The net margin for Charles River Laboratories International Inc stands at 0.0. The total capital return value is set at 0.04. Equity return is now at value 0.45, with 0.20 for asset returns.
Based on Charles River Laboratories International Inc (CRL), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at 0.27. The debt to equity ratio resting at 0.79. The interest coverage ratio of the stock is 2.08.
Currently, EBITDA for the company is 581.14 million with net debt to EBITDA at 4.35. When we switch over and look at the enterprise to sales, we see a ratio of 2.24. The receivables turnover for the company is 5.62for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.41.
Conclusion
In conclusion, Charles River Laboratories International Inc (CRL) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
